Coherus Oncology, Inc. (CHRS)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Coherus Oncology’s adjusted EPS topped expectations while revenue came in line in the second fiscal quarter of 2026, reported August 5, 2026, with revenue rising 39.5% to roughly $14.3 million (up from about $10.3 million a year ago) alongside a portfolio spanning cancer immunotherapies and biosimilars such as UDENYCA, YUSIMRY, and CIMERLI. Adjusted EPS was -$0.19, topping the -$0.25 estimate by $0.06 and improving from -$0.34 a year ago, while revenue of $14.3 million was in line with the $14.4 million consensus (-0.7%). Profitability was mixed, with gross profit of about $10.1 million translating to a gross margin of 70.4% even as the company posted an operating loss of roughly $32.3 million. Net income was a loss of about $20.6 million, improving 50.1% from a loss of around $41.3 million in the year-ago quarter. For the next period, consensus calls for EPS of -$0.21 on revenue of $16.0 million.
Next report — what to expect
Coherus Oncology, Inc. (CHRS) is set to report earnings on November 5, 2026. Wall Street’s next-period consensus calls for EPS of -$0.21 on revenue of $16.0 million. For trailing context, revenue grew +39.5% year over year last quarter. CHRS has beaten EPS in 4 of 8 most recent quarters.
About Coherus Oncology, Inc.
Coherus Oncology, Inc. is a U.S. biotechnology company focused primarily on researching, developing, and commercializing cancer immunotherapies, while also marketing a small portfolio of biosimilar medicines in supportive care, immunology, and ophthalmology. Listed on NASDAQ as CHRS, it generated $42.2 million of revenue in FY2025.
Today's Snapshot
The day ended with CHRS 3.8% lower at 1.01, in line with a weaker sector. Volume was about half of its usual level. Earnings are due from CHRS on 5 November.
Trading Volume
Below 10d avg (1.2M)
640.1K
vs S&P 500 Today
Strong Underperformance
-3.29%
Updated: October 23, 2026 at 20:13 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1.03 - $1.43Sell
- RSI (14)40.51Neutral
- Stochastic %K (14, 3, 3)39.61Neutral
- MACD Level (12, 26)-0.06Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.